A gym member’s honest guide to the medication everyone is talking about
I want to start by acknowledging something. The conversation around GLP-1 medications has gotten loud, and a lot of the noise is not helpful. You have heard the names. Ozempic. Wegovy. Mounjaro. Zepbound. Depending on who you follow, these drugs are either the greatest breakthrough in medicine or a shortcut that is eroding personal responsibility. I think both of those takes miss the mark, and I want to give you something more useful: a clear, honest breakdown of what these medications actually are and how they work.
The Biology First
GLP-1 stands for glucagon-like peptide-1. Your body already makes this hormone naturally. Your small intestine releases it after you eat as part of a chain of signals telling your brain and pancreas: we have taken in food, slow digestion down, release insulin to manage blood sugar, and start winding down the hunger signal. It is one of several hormonal tools your body uses to regulate appetite and blood sugar after a meal.
Here is the catch. Natural GLP-1 lasts only a few minutes before enzymes break it down. The medications we are talking about are engineered synthetic versions of this hormone designed to stay active in your body for days rather than minutes. That extended duration is what makes them pharmacologically significant.
Tirzepatide, sold as Mounjaro and Zepbound, goes a step further. It activates both GLP-1 receptors and GIP receptors simultaneously, making it a dual agonist. Head-to-head trial data suggests tirzepatide produces greater average weight loss than semaglutide, though the direct comparison research base is still relatively early.1
What These Medications Actually Do
GLP-1 receptor agonists reduce appetite and food intake through several mechanisms. They slow how quickly food moves through your stomach, which extends feelings of fullness. They act on receptors in the hypothalamus and other brain regions involved in appetite regulation. The primary driver of weight loss appears to be a meaningful, sustained reduction in caloric intake.
A 2026 systematic review and meta-analysis of 16 randomized controlled trials confirmed that among all GLP-1 based pharmacotherapies studied, semaglutide and tirzepatide produced the greatest reductions in body weight versus placebo or comparators.2 The STEP 1 randomized controlled trial showed a mean weight reduction of 14.9 percent in the semaglutide group versus 2.4 percent with placebo at 68 weeks, with both groups receiving lifestyle intervention.3 The SURMOUNT-1 trial for tirzepatide showed mean reductions of approximately 20.9 percent at the highest dose versus 3.1 percent with placebo at 72 weeks.4 These are results from tightly controlled clinical trials with regular lifestyle support, and real-world individual outcomes vary.
A Note on Food Noise
One of the most consistent things patients report when beginning GLP-1 medications is a quieting of what clinicians have started calling “food noise.” I have heard this described as the relentless mental preoccupation with food that some people experience, the intrusive thoughts about eating, the inability to feel truly satisfied, the cravings that feel almost impossible to override. Many patients describe the silencing of this as one of the most meaningful changes they experience.
Drs. Spencer and Karl Nadolsky of the Docs Who Lift podcast have discussed this extensively based on their clinical experience. I want to be accurate here: food noise is primarily a patient-reported phenomenon. There is early neuroimaging research suggesting GLP-1 medications may reduce activity in brain reward regions, but the mechanisms are not yet fully established in the peer-reviewed literature, and individual responses vary considerably. What I can say is that patients who describe significant food noise before starting these medications often report that this change alone is more meaningful to them than the number on the scale.
A Quick History
The GLP-1 research lineage traces partly back to observations of a peptide in Gila monster venom in the 1990s that had structural similarities to human GLP-1. That discovery eventually contributed to liraglutide, then once-weekly semaglutide, and now tirzepatide. These medications were originally developed for type 2 diabetes. The weight loss outcomes were initially secondary findings that turned out to be clinically significant enough to pursue separate obesity indications. The STEP 1 and SURMOUNT-1 trials referenced above were among the pivotal studies that led to FDA approval for weight management specifically.
These medications are tools. They work with your body’s hormonal signaling to reduce appetite and food intake. They are most effective when combined with structured nutrition and physical activity. That is not a disclaimer. That is the actual mechanism. Understanding the biology makes it easier to use them intelligently, whether you are taking them yourself or simply trying to understand what a member, client, or someone you care about is navigating.
If you’re looking to work with me or my team, check out our physique transformation program here.
Blog 1: Sources
- Docs Who Lift: Weight Loss Medicine: GLP-1s. Drs. Karl and Spencer Nadolsky. docswholift.com
- Docs Who Lift: GLP-1 Genetics: Predicting Weight Loss and Side Effects With Dr. Adam Auton. April 21, 2026. docswholift.com
- 1. Munawar N et al. Tirzepatide vs. Semaglutide for Weight Loss: Systematic Review and Meta-Analysis. Cureus. 2025;17(6):e86080. PMID: 40666599.
- 2. Ahmad N et al. GLP-1 receptor agonists for weight loss: systematic review and meta-analysis of RCTs. 2026. PMC12991648.
- 3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- 4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
